|
Insights from the Lhasa Limited and IPEC Europe Nitrites collaborative meeting
|
|
1
|
531
|
June 16, 2024
|
|
Method of Analysis for N nitroso Diclofenac and Quetiapine
|
|
11
|
1988
|
June 14, 2024
|
|
A New Framework for Identifying Nitrosamine Risks
|
|
1
|
649
|
June 13, 2024
|
|
Tetrazole nitrosamines
|
|
1
|
288
|
June 13, 2024
|
|
On the role of digital tools in nitrosamine risk assessment for drug substance and drug product manufacturing processes -Pub
|
|
0
|
204
|
June 13, 2024
|
|
ICH M7 plans to harmonize AI limits for Nitrosamines
|
|
1
|
315
|
June 13, 2024
|
|
Quelles Nitrosamines la Picloxidine est-elle susceptible de former?
|
|
1
|
324
|
June 12, 2024
|
|
N-Nitroso Hydrochlorothiazide in Hydrochlorothiazide drug substance
|
|
12
|
4183
|
June 11, 2024
|
|
EMA-funded project to predict in-vivo mutagenicity / mutagenicity classification
|
|
9
|
1047
|
June 11, 2024
|
|
Nitrosamines in food raise a health concern (EFSA)
|
|
7
|
1087
|
June 11, 2024
|
|
Limit for API having two NDSRI
|
|
14
|
2392
|
June 11, 2024
|
|
Lhasa TD50 or Gold TD50 to set AI limit?
|
|
8
|
737
|
June 10, 2024
|
|
CPCA Category 5 (AI 1500 ng/day) for NDIPA by Health Canada
|
|
2
|
473
|
June 6, 2024
|
|
Examining the Use of Surrogates in Combination with The Carcinogenic Potency Categorization Approach when Establishing Acceptable Intake Limits of N-Nitrosamine Impurities
|
|
0
|
477
|
June 9, 2024
|
|
Structuring expert review using AOPs: Enabling robust weight-of-evidence assessments for carcinogenicity under ICH S1B(R1)
|
|
0
|
284
|
June 9, 2024
|
|
Aspartame and nitrosamines
|
|
4
|
457
|
June 7, 2024
|
|
Lactose, Nitrosamine Risk?
|
|
35
|
3380
|
April 6, 2022
|
|
N-nitroso derivative of pyrrole moiety in Pyrrolopyrimidines
|
|
0
|
312
|
June 6, 2024
|
|
A new root cause? NOx
|
|
13
|
1930
|
November 17, 2023
|
|
Can Activated carbon promote nitrosamine formation and lead to high Nitrosamine levels in FP?
|
|
12
|
1091
|
June 5, 2024
|
|
Update: EFPIA workflows for Quality Risk management Jun 2024 v03
|
|
2
|
919
|
June 4, 2024
|
|
Nitrosamines impurities and ICH M7
|
|
1
|
311
|
June 4, 2024
|
|
🇨🇦 Health Canada updated the guidance and Appendix 1(March 15, 2024)
|
|
11
|
3311
|
June 3, 2024
|
|
Formic acid-aided sample preparation method for sensitive and simultaneous analysis of eight nitrosamines in poorly-water soluble pharmaceutical drugs using liquid chromatography–ultraviolet detection
|
|
0
|
251
|
June 2, 2024
|
|
🇺🇸 FDA - Fiscal Year 2024 Generic Drug Science and Research Initatives Public Workshop
|
|
20
|
1945
|
September 5, 2024
|
|
🇰🇷 Case study on the Occurrence of Impurities in Pharmaceuticals (Focusing on NDMA Cases)
|
|
0
|
335
|
May 31, 2024
|
|
N-nitroso-nitrofurantoin
|
|
0
|
288
|
May 31, 2024
|
|
Formaldehyde Catalysis of Nitrosamine Formation
|
|
3
|
645
|
May 31, 2024
|
|
⚙️🌎CPCA: the gestation, birth, and development -Pub
|
|
5
|
1169
|
May 31, 2024
|
|
Justify the presence of amine in the API chemical structure
|
|
3
|
303
|
May 29, 2024
|